Monthly Archives: August 2021

Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students

Posted on by

Journal of Community Health
Volume 46, issue 4, August 2021
https://link.springer.com/journal/10900/volumes-and-issues/46-4

 

Article
Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students
Authors (first, second and last of 8) Eric Richardson, Kathleen A. Ryan, Stephanie A. S. Staras,
Content type: Original Paper
Open Access
Published: 02 January 2021
Pages: 808 – 816

Overview of the Issue

Posted on by

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 32, Number 2, May 2021 Supplement
https://muse.jhu.edu/issue/44396

 

Table of Contents
Overview of the Issue
Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark
…The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.
This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care…

Voluntary COVID-19 vaccination of children: a social responsibility

Posted on by

Journal of Medical Ethics
August 2021 – Volume 47 – 8
http://jme.bmj.com/content/current

 

COVID-19 current controversies
Voluntary COVID-19 vaccination of children: a social responsibility (11 June, 2021) Free
Margherita Brusa, Yechiel Michael Barilan
Abstract
Nearly 400 million adults have been vaccinated against COVID-19. Children have been excluded from the vaccination programmes owing to their lower vulnerability to COVID-19 and to the special protections that apply to children’s exposure to new biological products. WHO guidelines and national laws focus on medical safety in the process of vaccine approval, and on national security in the process of emergency authorisation. Because children suffer much from social distancing, it is argued that the harms from containment measures should be factored in a broader perspective on the good of the child. Considering the available knowledge on the disease, vaccine, and coping strategies, the decision about vaccine access to children is a public responsibility. The ultimate choice is a matter of paediatric informed consent. Moreover, jurisdictions that permit non-participation in established childhood vaccination programmes should also permit choice of vaccines outside of the approved programmes. Even if vaccine supply is too short to cover the paediatric population, the a priori exclusion of children is unjust. It may also exacerbate local and global inequalities. The second part of the paper delineates a prudent and ethical scheme for gradual incorporation of minors in vaccination programmes that includes a rigorous postvaccination monitoring. This is a theoretical paper in ethics that uses the Pfizer vaccine as a stock example, without discussing possible differences among existing vaccines. The key purpose is reflection on the good of the child in emergencies and vaccine policymaking.

7-1-7: an organising principle, target, and accountability metric to make the world safer from pandemics

Posted on by

The Lancet
Aug 14, 2021 Volume 398 Number 10300 p559-640
https://www.thelancet.com/journals/lancet/issue/current

 

Viewpoint
7-1-7: an organising principle, target, and accountability metric to make the world safer from pandemics
Thomas R Frieden, Christopher T Lee, Aaron F Bochner, Marine Buissonnière, Amanda McClelland
Introduction
COVID-19 makes it both possible and necessary to review lessons learnt from recent epidemics, re-evaluate approaches, and develop a framework that accelerates progress to make the world safer from epidemics. Every country and every community must be able to rapidly detect, report, and respond effectively to any potential major new health threat. Notably, wide variation in capacities exist across countries.1,  2 To improve early detection and rapid control of health threats, clear performance targets need to be set, cross-country variations need to be better quantified, factors responsible for these variations need to be identified, and speed and quality of detection and response need to be improved.3

Since the west Africa Ebola epidemic of 2014–16, several frameworks have been developed to measure readiness capacity. These frameworks focus on discrete components of health systems (eg, laboratory, surveillance4,  5 and universal health coverage6 ) rather than overall system performance, and do not adequately account for less easily measurable capacities, such as access to rapid financing and logistics, transparency, governance, leadership, or overall system fairness.7

How fast a system detects and responds effectively to a threat is the optimal measure of performance.8, 9 Continuously evaluating and improving timeliness can identify performance bottlenecks and help to accelerate progress, improving detection speed and response quality.8, 9, 10, 11 Timeliness metrics have been integrated into the WHO after-action review process 12 and the Triple Billion targets for its 13th General Programme of Work (GPW13).13 However, clear targets for time to detection and response have not yet been described. These metrics can supplement existing capacity measurements of the International Health Regulations (2005), including the Joint External Evaluation, which have been shown to be useful but not sufficient to predict effective response to COVID-19.2

The COVID-19 pandemic provides a galvanising moment to set clear and ambitious goals to promote accountability and to align stakeholders, including communities, countries, global health institutions, and donors. Ambitious but achievable goals are an essential communication tool to improve the identification and control of health threats. Establishing objectively verifiable benchmarks will give countries clear guidance, will give partners, civil society, WHO, and donors a clear pathway forward for measurement, accountability, and improvement, and will help governments and civil society to focus attention and resources.

Part of the reluctance to fund health preparedness stems from the absence of simple measurements of progress. One reason for broad support for the global initiatives against HIV and malaria has been the appeal, to politicians and voters alike, of clear metrics: the number of people treated, the bednets distributed, and the lives saved. For HIV, the 90-90-90 goal established by the UN 14 —ensuring that 90% of people infected with HIV know their status, 90% of those diagnosed receive sustained treatment, and 90% of patients receiving treatment have undetectable viral load—translated evidence of the benefits of antiretroviral therapy into targets for harmonised global action on solid, life-saving outcomes.15 Generating enthusiasm and support for a public health programme is easier if it has a performance metric that is straightforward, easily remembered, and will catalyse progress on the problem being addressed.

We suggest a new global target of 7-1-7 (panel) whereby every suspected outbreak is identified within 7 days of emergence, reported to public health authorities with initiation of investigation and response efforts within 1 day, and effectively responded to—as defined by objective benchmarks—within 7 days (appendix p 1). This 7-1-7 target can provide a global basis for accountability, be applied at country level to assess and improve performance, and can also be applied locally to promote equity in detection and context-appropriate response capabilities…

Delivery channels and socioeconomic inequalities in coverage of reproductive, maternal, newborn, and child health interventions: analysis of 36 cross-sectional surveys in low-income and middle-income countries

Posted on by

Lancet Global Health
Aug 2021 Volume 9 Number 8 e1028-e1175
https://www.thelancet.com/journals/langlo/issue/current

 

Delivery channels and socioeconomic inequalities in coverage of reproductive, maternal, newborn, and child health interventions: analysis of 36 cross-sectional surveys in low-income and middle-income countries
Daniel G P Leventhal, Inácio Crochemore-Silva, Luis P Vidaletti, Nancy Armenta-Paulino, Aluísio J D Barros, Cesar G Victora

Completeness of reporting and risks of overstating impact in cluster randomised trials: a systematic review

Posted on by

Lancet Global Health
Aug 2021 Volume 9 Number 8 e1028-e1175
https://www.thelancet.com/journals/langlo/issue/current

 

Health Policy
Completeness of reporting and risks of overstating impact in cluster randomised trials: a systematic review
Elizabeth L Turner, et al. on behalf of the CRT Binary Outcome Reporting Group
Summary
Overstating the impact of interventions through incomplete or inaccurate reporting can lead to inappropriate scale-up of interventions with low impact. Accurate reporting of the impact of interventions is of great importance in global health research to protect scarce resources. In global health, the cluster randomised trial design is commonly used to evaluate complex, multicomponent interventions, and outcomes are often binary. Complete reporting of impact for binary outcomes means reporting both relative and absolute measures. We did a systematic review to assess reporting practices and potential to overstate impact in contemporary cluster randomised trials with binary primary outcome. We included all reports registered in the Cochrane Central Register of Controlled Trials of two-arm parallel cluster randomised trials with at least one binary primary outcome that were published in 2017. Of 73 cluster randomised trials, most (60 [82%]) showed incomplete reporting. Of 64 cluster randomised trials for which it was possible to evaluate, most (40 [63%]) reported results in such a way that impact could be overstated. Care is needed to report complete evidence of impact for the many interventions evaluated using the cluster randomised trial design worldwide.

Polio eradication at the crossroads

Posted on by

Lancet Global Health
Aug 2021 Volume 9 Number 8 e1028-e1175
https://www.thelancet.com/journals/langlo/issue/current

 

Polio eradication at the crossroads
Konstantin Chumakov, Ellie Ehrenfeld, Vadim I Agol, Eckard Wimmer
Summary
The Global Polio Eradication Initiative, launched in 1988 with anticipated completion by 2000, has yet to reach its ultimate goal. The recent surge of polio cases urgently calls for a reassessment of the programme’s current strategy and a new design for the way forward. We propose that the sustainable protection of the world population against paralytic polio cannot be achieved simply by stopping the circulation of poliovirus but must also include maintaining high rates of population immunity indefinitely, which can be created and maintained by implementing global immunisation programmes with improved poliovirus vaccines that create comprehensive immunity without spawning new virulent viruses. The proposed new strategic goal of eradicating the disease rather than the virus would lead to a sustainable eradication of poliomyelitis while simultaneously promoting immunisation against other vaccine-preventable diseases.

Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study

Posted on by

Lancet Infectious Diseases
Aug 2021 Volume 21 Number 8 p1051-1192, e208-e257
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study
Peter C Jentsch, Madhur Anand, Chris T Bauch
Summary
During the COVID-19 pandemic, authorities must decide which groups to prioritise for vaccination in a shifting social–epidemiological landscape in which the success of large-scale non-pharmaceutical interventions requires broad social acceptance. We aimed to compare projected COVID-19 mortality under four different strategies for the prioritisation of SARS-CoV-2 vaccines.
We developed a coupled social–epidemiological model of SARS-CoV-2 transmission in which social and epidemiological dynamics interact with one another. We modelled how population adherence to non-pharmaceutical interventions responds to case incidence. In the model, schools and workplaces are also closed and reopened on the basis of reported cases. The model was parameterised with data on COVID-19 cases and mortality, SARS-CoV-2 seroprevalence, population mobility, and demography from Ontario, Canada (population 14·5 million). Disease progression parameters came from the SARS-CoV-2 epidemiological literature. We assumed a vaccine with 75% efficacy against disease and transmissibility. We compared vaccinating those aged 60 years and older first (oldest-first strategy), vaccinating those younger than 20 years first (youngest-first strategy), vaccinating uniformly by age (uniform strategy), and a novel contact-based strategy. The latter three strategies interrupt transmission, whereas the first targets a vulnerable group to reduce disease. Vaccination rates ranged from 0·5% to 5% of the population per week, beginning on either Jan 1 or Sept 1, 2021…

Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study

Posted on by

Lancet Public Health
Aug 2021 Volume 6 Number 8 e534-e619
https://www.thelancet.com/journals/lanpub/issue/current

 

Articles
Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study
Courtney R Lane, et al.
A cornerstone of Australia’s ability to control COVID-19 has been effective border control with an extensive supervised quarantine programme. However, a rapid recrudescence of COVID-19 was observed in the state of Victoria in June, 2020. We aim to describe the genomic findings that located the source of this second wave and show the role of genomic epidemiology in the successful elimination of COVID-19 for a second time in Australia.

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Posted on by

Nature
Volume 596 Issue 7871, 12 August 2021
https://www.nature.com/nature/volumes/596/issues/7871

 

Article | 09 June 2021 | Open Access
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Analysis of the immunogenicity of the Ad26.COV2.S vaccine against the B1.351 and P.1 SARS-CoV-2 variants of concern shows reduced neutralization antibody titres, but comparable T cell responses and antibody-dependent effector functions.
Galit Alter, Jingyou Yu, Dan H. Barouch

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Posted on by

Nature
Volume 596 Issue 7871, 12 August 2021
https://www.nature.com/nature/volumes/596/issues/7871

 

Article | 10 June 2021
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Samples of serum from individuals immunized with the BNT162b2 vaccine show neutralization activity against engineered SARS-CoV-2s bearing the spike mutations from B.1.617 and other variants.
Jianying Liu, Yang Liu, Pei-Yong Shi

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Posted on by

Nature
Volume 596 Issue 7871, 12 August 2021
https://www.nature.com/nature/volumes/596/issues/7871

 

Article | 08 July 2021
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
The SARS-CoV-2 Delta variant partially evades neutralization by several monoclonal antibodies and by sera from individuals who have had COVID-19, but two doses of anti-COVID-19 vaccines still generate a strong neutralizing response.
Delphine Planas, David Veyer, Olivier Schwartz

Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank

Posted on by

Nature Genetics
Volume 53 Issue 7, July 2021
https://www.nature.com/ng/volumes/53/issues/7

 

Perspective | 28 June 2021
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
The UK Biobank Exome Sequencing Consortium aims to sequence all the exomes of approximately 500,000 UK Biobank participants. This Perspective describes the results from approximately 200,000 exomes and discusses the lessons learned from this UK Biobank–biopharmaceutical company collaboration.
Joseph D. Szustakowski, Suganthi Balasubramanian, Zhan Ye

A review and agenda for integrated disease models including social and behavioural factors

Posted on by

Nature Human Behaviour
Volume 5 Issue 7, July 2021
https://www.nature.com/nathumbehav/volumes/5/issues/7

 

Review Article | 28 June 2021
A review and agenda for integrated disease models including social and behavioural factors
Social and behavioural factors impact the emergence, spread and control of human disease. This paper reviews current disease modelling methodologies and the challenges and opportunities for integration with data from social science research and risk communication and community engagement practice.
Jamie Bedson, Laura A. Skrip, Benjamin M. Althouse

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Posted on by

Nature Medicine
Volume 27 Issue 8, August 2021
https://www.nature.com/nm/volumes/27/issues/8

 

Article | 09 June 2021 | Open Access
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
Results from the Office of National Statistics COVID-19 Infection Survey in the United Kingdom demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.
Emma Pritchard, Philippa C. Matthews, Koen B. Pouwels

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Posted on by

Nature Medicine
Volume 27 Issue 8, August 2021
https://www.nature.com/nm/volumes/27/issues/8

 

Article | 14 June 2021 | Open Access
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
At early time points after vaccination with a single dose or two doses of the BNT162b2 mRNA COVID-19 vaccine, breakthrough SARS-CoV-2 infections can be disproportionately caused by the B.1.1.7 or B.1.351 variants of concern, underlining the need to ensure rapid and complete vaccination.
Talia Kustin, Noam Harel, Adi Stern

COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries

Posted on by

Nature Medicine
Volume 27 Issue 8, August 2021
https://www.nature.com/nm/volumes/27/issues/8

 

Article | 16 July 2021 | Open Access
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries
Survey data collected across ten low-income and middle-income countries (LMICs) in Asia, Africa and South America compared with surveys from Russia and the United States reveal heterogeneity in vaccine confidence in LMICs, with healthcare providers being trusted sources of information, as well as greater levels of vaccine acceptance in these countries than in Russia and the United States.
Julio S. Solís Arce, Shana S. Warren, Saad B. Omer

Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection

Posted on by

Nature Medicine
Volume 27 Issue 8, August 2021
https://www.nature.com/nm/volumes/27/issues/8

 

Article | 24 June 2021
Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection
Multiyear analysis of antibody responses in recipients of the dengue vaccine Dengvaxia in the Philippines supports their utility as a predictor of protection against disease, and reveals that Dengvaxia efficacy declines 3 years after complete vaccination.
Henrik Salje, Maria Theresa Alera, Alan L. Rothman

Advances and opportunities in malaria population genomics

Posted on by

Nature Reviews Genetics
Volume 22 Issue 8, August 2021
https://www.nature.com/nrg/volumes/22/issues/8

 

Review Article | 08 April 2021
Advances and opportunities in malaria population genomics
In this Review, Neafsey, Taylor and MacInnis discuss how population genomics approaches are currently used to study malaria parasites and mosquito vectors. They explore information that can be derived from such genomics approaches and discuss the use of relatedness-based measures of population variation to understand parasite and vector dynamics at highly resolved spatiotemporal scales.
Daniel E. Neafsey, Aimee R. Taylor, Bronwyn L. MacInnis

Understanding COVID-19 in Africa

Posted on by

Nature Reviews Immunology
Volume 21 Issue 8, August 2021
https://www.nature.com/nri/volumes/21/issues/8

 

Comment | 24 June 2021
Understanding COVID-19 in Africa
In this Comment article, Sofonias Tessema and John Nkengasong provide an overview of the current state of the COVID-19 pandemic in Africa and the challenges posed by the triple burden of emerging, endemic and non-communicable diseases.
Sofonias K. Tessema, John N. Nkengasong

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Posted on by

Nature Reviews Immunology
Volume 21 Issue 8, August 2021
https://www.nature.com/nri/volumes/21/issues/8

 

Progress | 01 July 2021
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
This Progress article summarizes our current understanding of the immune mechanisms of protection induced by the available COVID-19 vaccines. The authors compare vaccine-induced antibody responses following one or two doses of different vaccines and consider the relative importance of neutralizing antibodies for vaccine-mediated protection against SARS-CoV-2.
Manish Sadarangani, Arnaud Marchant, Tobias R. Kollmann

Trust in Science: a novel research partnership model in Latin America

Posted on by

Nature Reviews Drug Discovery
Volume 20 Issue 8, August 2021
https://www.nature.com/nrd/volumes/20/issues/8

 

Comment | 12 April 2021
Trust in Science: a novel research partnership model in Latin America
Ten years ago, GlaxoSmithKline established an innovative model for public–private research partnerships in Latin America known as Trust in Science. Here, we summarize this novel initiative, illustrate its achievements in terms of scientific advances and local talent development, and highlight the key learnings that could be applied to similar initiatives.
Israel S. Gloger, Rosana Felice, Kevin P. Madauss

Use of lay vaccinators in animal vaccination programmes: A scoping review

Posted on by

PLoS Neglected Tropical Diseases
http://www.plosntds.org/

 

Use of lay vaccinators in animal vaccination programmes: A scoping review
Christian Tetteh Duamor, Katie Hampson, Felix Lankester, Maganga Sambo, Katharina Kreppel, Sally Wyke, Sarah Cleaveland
Research Article | published 10 Aug 2021 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0009691

Knowledge, acceptance and perception on COVID-19 vaccine among Malaysians: A web-based survey

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 14 Aug 2021]

 

Knowledge, acceptance and perception on COVID-19 vaccine among Malaysians: A web-based survey
Nurul Azmawati Mohamed, Hana Maizuliana Solehan, Mohd Dzulkhairi Mohd Rani, Muslimah Ithnin, Che Ilina Che Isahak
Research Article | published 13 Aug 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0256110

Shifting research priorities in maternal and child health in the COVID-19 pandemic era in India: A renewed focus on systems strengthening

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 14 Aug 2021]

 

Shifting research priorities in maternal and child health in the COVID-19 pandemic era in India: A renewed focus on systems strengthening
Kayur Mehta, Sanjay Zodpey, Preetika Banerjee, Stephanie L. Pocius, Baldeep K. Dhaliwal, Andrea DeLuca, Sangeeta Das Bhattacharya, Shailendra Hegde, Paramita Sengupta, Madhu Gupta, Anita Shet
Research Article | published 12 Aug 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0256099

Influenza vaccination hesitancy in large urban centers in South America. Qualitative analysis of confidence, complacency and convenience across risk groups

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 14 Aug 2021]

 

Influenza vaccination hesitancy in large urban centers in South America. Qualitative analysis of confidence, complacency and convenience across risk groups
Miguel Ángel González-Block, Blanca Estela Pelcastre-Villafuerte, Daniela Riva Knauth, Andréa Fachel-Leal, Yamila Comes, Pedro Crocco, Laura Noboa, Berenice Rodríguez Zea, Mónica Ruoti, Sandra Patricia Díaz Portillo, Elsa Sarti
Research Article | published 12 Aug 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0256040

Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys

Posted on by

PNAS – Proceedings of the National Academy of Sciences of the United States of America
July 27, 2021; vol. 118 no. 31
https://www.pnas.org/content/118/31

 

Statistics
Open Access
Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys
Nicholas J. Irons and Adrian E. Raftery
PNAS August 3, 2021 118 (31) e2103272118; https://doi.org/10.1073/pnas.2103272118

Quantifying COVID-19 importation risk in a dynamic network of domestic cities and international countries

Posted on by

PNAS – Proceedings of the National Academy of Sciences of the United States of America
July 27, 2021; vol. 118 no. 31
https://www.pnas.org/content/118/31

 

Environmental Sciences
Quantifying COVID-19 importation risk in a dynamic network of domestic cities and international countries
Xiaoyi Han, Yilan Xu, Linlin Fan, Yi Huang, Minhong Xu, and Song Gao
PNAS August 3, 2021 118 (31) e2100201118; https://doi.org/10.1073/pnas.2100201118

Interdisciplinary Theory, Methods, and Approaches for Hazards and Disaster Research: An Introduction to the Special Issue

Posted on by

Risk Analysis
Volume 41, Issue 7 Pages: 1047-1253 July 2021
https://onlinelibrary.wiley.com/toc/15396924/current

 

Special Issue: Interdisciplinary Theory, Methods, and Approaches for Hazards and Disaster Research
Original Research Articles
Interdisciplinary Theory, Methods, and Approaches for Hazards and Disaster Research: An Introduction to the Special Issue
Lori Peek, Seth Guikema
Pages: 1047-1058
First Published: 28 June 2021
Abstract
What is interdisciplinary research? Why is it vital to the advancement of the field of hazards and disaster research? What theory, methods, and approaches are fundamental to interdisciplinary research projects and their applications? This article addresses these and other pressing questions by taking stock of recent advancements in interdisciplinary studies of hazards and disasters. It also introduces the special issue of Risk Analysis, which includes this introductory article and 25 original perspectives papers meant to highlight new trends and applications in the field. The papers were written following two National Science Foundation-supported workshops that were organized in response to the growing interest in interdisciplinary hazards and disaster research, the increasing number of interdisciplinary funding opportunities and collaborations in the field, and the need for more rigorous guidance for interdisciplinary researchers and research teams. This introductory article and the special collection are organized around the cross-cutting themes of theory, methods, approaches, interdisciplinary research projects, and applications to advance interdisciplinarity in hazards and disaster research.

Community engagement and vulnerability in infectious diseases: A systematic review and qualitative analysis of the literature

Posted on by

Social Science & Medicine
Volume 284 September 2021
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/284/suppl/C

 

Review article Open access
Community engagement and vulnerability in infectious diseases: A systematic review and qualitative analysis of the literature
Jacob Osborne, John Paget, Tamara Giles-Vernick, Ruth Kutalek, … Michel Dückers
Article 114246

Emerging issues in COVID-19 vaccination in tropical areas: Impact of the immune response against helminths in endemic areas

Posted on by

Travel Medicine and Infectious Diseases
Volume 42 July–August 2021
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/42/suppl/C

 

Editorial No access
Emerging issues in COVID-19 vaccination in tropical areas: Impact of the immune response against helminths in endemic areas
Leonor Chacin-Bonilla, Nathalie Chacón-Fonseca, Alfonso J. Rodriguez-Morales
Article 102087

Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines

Posted on by

Vaccine
Volume 39, Issue 31 Pages 4239-4390 (13 July 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/31

 

Discussion Full text access
Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines
Richard K. Zimmerman
Pages 4242-4244